A biomarker for these malignancies is the frequently detectable high expression of PD-L1 (CD274 and also known as B7-H1) in EBV+ PTLD, cHL, and DLBCL (10–12). The gene discussed is CD274; the disease is post-transplant lymphoproliferative disease.